Compare Abeona Therapeutics Inc (ABEO) vs Dover Corp (DOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dover Corp — how do they compare? Abeona Therapeutics Inc trades at $6.29 (market cap $425.47M), while Dover Corp trades at $206.81 (market cap $28.02B). The key difference: Dover Corp is far larger — about 65.9× Abeona Therapeutics Inc's market cap, and Dover Corp pays a 1.01% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DOV | |
|---|---|---|
Market Cap | $425.47M | $28.02B |
Sector | Health | Industrials |
52-Week High | $7.46 | $233.31 |
52-Week Low | $4.17 | $161.16 |
Enterprise Value | $280.37M | $29.53B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Dover Corporation (DOV) trades at $208.07, down 0.97% on the day, with strong analyst support showing 19 buy ratings and a $232.33 consensus price target. The company demonstrates solid fundamentals with consistent earnings beats, a 13.48% net income margin, and recent dividend increases. Technical indicators show a bearish short-term signal despite neutral oscillators, with key support at $205.
DOV presents a compelling investment case with strong profitability, dividend growth, and raised 2026 guidance, though near-term technical weakness and acquisition integration risks warrant monitoring. The stock offers approximately 11.7% upside to analyst targets with no sell ratings among 28 covering firms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
